Results 91 to 100 of about 16,334 (217)

Renal dysfunction in symptomatic Waldenström macroglobulinaemia: A nationwide Italian multicentre study

British Journal of Haematology, Volume 208, Issue 6, Page 2059-2068, June 2026.
Renal dysfunction represents a possible underrecognized complication of symptomatic WM; this condition correlates with adverse global and disease‐specific clinical outcomes. Summary The prognostic significance of impaired renal function in Waldenström macroglobulinaemia (WM) remains poorly defined.
Nicolò Danesin, Francesco Autore, Anna Maria Frustaci, Gianmarco Favrin, Emanuele Cencini, Alessandro Noto, Irene Dogliotti, Jacopo Olivieri, Marcello Riva, Isacco Ferrarini, Anna Maria Barbui, Sara Steffanoni, Dario Marino, Benedetta Puccini, Piero Maria Stefani, Rita Rizzi, Michele Merli, Angela Ferrari, Stefano Luminari, Carlo Visco, Livio Trentin, Andrea Visentin, Annarita Conconi, Simone Ferrero, Marzia Varettoni, Alessandra Tedeschi, Luca Laurenti, Francesco Piazza   +27 more
wiley   +1 more source

Antiphospholipid syndrome, monoclonal gammopathy, and cryoglobulinemia overlap leading to recurrent cutaneous microvascular thrombosis: A case report and retrospective cohort study

eJHaem
Antiphospholipid syndrome (APS), cryoglobulinemia, and monoclonal gammopathies are variably accompanied by thrombotic complications. We describe a patient with recurrent skin microvascular thrombosis, APS, cryoglobulinemia, marginal zone lymphoma, and ...
Alexandra Bohm, Bo Angela Wan, Amir Karin, Lauren J. Lee, Agnes Y. Y. Lee, Edward M. Conway, Chieh Min Benjamin Lai   +6 more
doaj   +1 more source

Circulating levels of insulin‐like growth factor I (IGF‐I) and risk of multiple myeloma: An observational and Mendelian randomisation study

British Journal of Haematology, Volume 208, Issue 6, Page 1942-1953, June 2026.
Summary Evidence for an association between insulin‐like growth factors (IGF) and multiple myeloma (MM) is inconsistent. We examined total IGF‐I concentrations and risk of MM by combining baseline serological data among UK Biobank participants (n = 444 187; 732 incident MM) with a two‐sample Mendelian randomisation (MR) analysis using identified ...
Yolanda Benavente, Sara Hermosa, Nikos Papadimitriou, Alyssa Clay‐Gilmour, Elizabeth E. Brown, Jonathan N. Hofmann, Nathaniel Rothman, Qing Lan, Sonja I. Berndt, Demetrius Albanes, Mark Purdue, Mitchell J. Machiela, Stephen J. Chanock, Parveen Bhatti, Wendy Cozen, Aaron Norman, Susan L. Slager, James R. Cerhan, Vincent Rajkumar, Shaji K. Kumar, Celine M. Vachon, Anne J. Novak, Thomas M. Habermann, Brian K. Link, Gilles Salles, Herve Ghesquieres, Paige M. Bracci, Elizabeth Holly, Rosalie G. Griffin, Michelle A. T. Hildebrandt, Roel C. H. Vermeulen, P. Martijn Kolijn, Henrik Hjalgrim, Karin Ekström Smedby, Harindra Jayasekara, Simon Cheah, Alain Monnereau, Yu Chen, Alan Arslan, Yawei Zhang, Nicola J. Camp, Douglas W. Sborov, Afaf E. G. Osman, Elad Ziv, Immaculata De Vivo, Vijai Joseph, Lauren R. Teras, Alpa V. Patel, Eleanor Kane, Claire M. Vajdic, Adrien Guilloteau, Pierluigi Cocco, Laia Alemany, Juan Sainz, James McKay, Brenda M. Birmann, Delphine Casabonne   +56 more
wiley   +1 more source

Biochemical bone biomarkers in plasma cell dyscrasias

British Journal of Haematology, Volume 208, Issue 6, Page 1909-1923, June 2026.
Visual abstract depicting that bone turnover markers reflect dynamic alterations in bone remodelling across the spectrum of plasma cell dyscrasias but remain limited by assay variability, biological confounding and incomplete integration with imaging and risk stratification.
Guido Nador, Rohit Vijjhalwar, Muhammad Kassim Javaid, Claire M. Edwards, Karthik Ramasamy   +4 more
wiley   +1 more source

Deciphering the full spectrum of Castleman diseases based on a cohort of 700 patients in a western country

British Journal of Haematology, Volume 208, Issue 6, Page 2036-2046, June 2026.
The spectrum of Castleman diseases has expanded over the past three decades. The phenotype of the diseases varies not only among the three major types but also according to the patient ancestry. Summary Under the Castleman disease (CD) eponym, three distinct diseases sharing common pathological features have been described over time.
Eric Oksenhendler, Marion Malphettes, Véronique Meignin, David Boutboul, Lionel Galicier   +4 more
wiley   +1 more source

Recognising disease progression in MGUS and smouldering myeloma: Biomarkers, symptom monitoring and imaging

British Journal of Haematology, Volume 208, Issue 6, Page 2079-2086, June 2026.
Summary The Tackling Early Morbidity and Mortality in Myeloma trial (TEAMM) trial recruited 977 newly diagnosed myeloma patients from 93 UK hospitals to assess the advantages and disadvantages of prophylactic antibiotics for the first 12 weeks. This paper analyses the 133 (14%) patients who had previously known precursor disease including monoclonal ...
Aidan Haslam, Gulnaz Iqbal, Mark Drayson, Guy Pratt, Kwee Yong, Janet Dunn, Catherine Atkin, Chris Bunce, Donna Howe, Stella Bowcock   +9 more
wiley   +1 more source

Enhancing antitumour response to proteasome inhibitors with inhibitors of insulin‐degrading enzyme, a new molecular vulnerability in multiple myeloma

British Journal of Pharmacology, Volume 183, Issue 12, Page 3355-3376, June 2026.
Inhibitors of insulin‐degrading enzyme boost PI cytotoxicity through an increased sensitivity of proteasome to PI inhibitors, induction of ISR, DNA damage and Myc down‐regulation. They overcome PI resistance in vitro and induce tumour regression in vivo.
Laetitia Lesire, Rebecca Deprez‐Poulain, Damien Bosc, Florence Leroux, Valerie Landry, Sarah Ourabah, Morgane Tardy, Clara Maillard, Ronan Gealageas, Julie Dumont, Adrien Herledan, Sandrine Warenghem, Manon Cruette, Celine Lenglart, Alexandre Biela, Catherine Piveteau, Eva De Smedt, Catharina Muylaert, Wenguang Liang, Elvira Garcia De Paco, Elina Alaterre, Sara Ovejero, Nicolas Robert, Fabien Delahaye, Wei‐Jen Tang, Peter van Endert, Elke De Bruyne, Jérôme Moreaux, Benoit Deprez   +28 more
wiley   +1 more source

Rate of MGUS Progression to Haematological Malignancies: A Systematic Review

European Journal of Haematology, Volume 116, Issue 6, Page 889-906, June 2026.
ABSTRACT Monoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic pre‐cancerous condition that precedes plasma cell dyscrasias, including multiple myeloma (MM). Current clinical guidelines report that MGUS's rate of malignant progression to haematological malignancy (HM) is ~1% per year; however, reported rates have varied widely ...
Stephen James Quinn, Chris Cardwell, Lesley Ann Anderson, Charlene McShane   +3 more
wiley   +1 more source

Patient With MGRS/PGNMID Without Detection of a Peripheral Clone: Case Report and Literature Review

Case Reports in Hematology
Monoclonal gammopathy of renal significance (MGRS) is a clonal cell proliferative disorder, characterized by the production of monoclonal immunoglobulins in patients that do not meet hematological criteria for a specific malignancy.
Agatha Larrazábal, Ana Ávila-Rodriguez, Matías Sánchez   +2 more
doaj   +1 more source

Increasing Trends of Minimal Residual Disease Measurement in Trials Focusing on Multiple Myeloma Treatment: A Systematic Analysis of Clinical Research Design From 2014 to 2025

European Journal of Haematology, Volume 116, Issue 6, Page 724-732, June 2026.
ABSTRACT Minimal residual disease (MRD) is a central biomarker in multiple myeloma (MM), offering unprecedented sensitivity for evaluating treatment efficacy and serving as a potential surrogate endpoint. We conducted a comprehensive analysis of clinical trials registered on ClinicalTrials.gov between 2014 and 2025.
Mimi Choon‐Quinones, George Dennis Obeng, Benjamin Asiedu‐Ayeh, Sampson Kawuo, Asmau Mohammed Tukur, Inusah Mohammed, Akosua Pokuaah Obeng, Jean‐Luc Harousseau, Anja Seckinger, Dirk Hose, Emmanuel Sarkodie, Attila Imre, Marcell Csanádi   +12 more
wiley   +1 more source